For a mother-to-be or a mother preparing for pregnancy, the term cord blood should not be unfamiliar. Most mothers do not know enough about cord blood, and mothers inevitably have some doubts! Next, I will give you some knowledge about cord blood. What exactly is cord blood? Where does it come from? Cord blood is the blood obtained from the umbilical vein when the mother delivers the fetus and the fetus breaks the umbilical cord in as short a time as possible. Cord blood is rich in hematopoietic stem cells, and its transplantation through hematopoietic stem cells can rebuild the body’s blood and immune system. Under certain conditions, it can save lives through medical technology. Cord blood, bone marrow and peripheral blood are the three major sources of hematopoietic stem cells. What are the advantages of hematopoietic stem cells from umbilical cord blood? Compared to the hematopoietic stem cells from bone marrow and peripheral blood, the hematopoietic stem cells from umbilical cord blood have greater advantages: easy collection, no pain and no side effects for mother and child physical storage, rapid treatment time (cord blood is physically stored in a cord blood bank approved by the Health and Welfare Commission, so the supply is more timely when needed) low contamination rate, etc.: biologically, with the recipient’s (recipient’s) human The biologic compatibility with the human leukocyte antigen (HLA) of the recipient (recipient) makes it less prone to rejection. Higher transplantation outcome. Current limitations of cord blood HSCT There are certain clinical requirements for the number of cells needed for HSCT. For cord blood, due to individual differences, the amount of blood collected from each baby’s cord blood is different and the number of cells can vary. To ensure effective future application, freezing is not recommended if the number of nucleated cells before freezing does not reach a certain standard. However, the in vitro expansion technology has gradually matured and clinical treatment with double cord blood or combined transplantation with peripheral blood is now available, addressing the need for high cell count hematopoietic stem cell transplantation in large weight patients. It should be noted that autologous cord blood transplantation does not suffer from mating problems and does not lose excessive cell counts due to rejection, so a smaller number of cord blood HSCs can meet the demand for autologous transplantation.